NVAX vs PTCT: fair value comparison
Novavax, Inc. and PTC Therapeutics, Inc. · Updated 2026-10-19
NVAX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PTCT is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, NVAX currently ranks higher by quality score.
| NVAX | PTCT | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $11.26 | $59.24 |
| 12-month range | $6.22–$12.82 | $59.24–$89.55 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #86 of 301 Healthcare | #87 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: NVAX fair value analysis · PTCT fair value analysis